Persistent effect of mTOR inhibition on preneoplastic foci progression and gene expression in a rat model of hepatocellular carcinoma

作者: Heather Francois-Vaughan , Adeola O. Adebayo , Kate E. Brilliant , Nicola M.A. Parry , Philip A. Gruppuso

DOI: 10.1093/CARCIN/BGW016

关键词:

摘要: Hepatocellular carcinoma (HCC) is a heterogeneous disease in which tumor subtypes can be identified based on the presence of adult liver progenitor cells. Having previously mTOR pathway as critical to cell proliferation model injury, we investigated temporal activation signaling rat hepatic carcinogenesis. The employed chemical carcinogens and partial hepatectomy induce marker-positive HCC. Immunohistochemical staining for phosphorylated ribosomal protein S6 indicated robust complex 1 (mTORC1) activity early preneoplastic lesions that peaked during first week waned over subsequent 10 days. Continuous administration rapamycin by subcutaneous pellet 70 days markedly reduced development focal lesions, but resulted PI3K pathway. To test hypothesis mTORC1 was progression foci, limited 3-week period at start protocol. Focal lesion burden degree indistinguishable from seen with continuous administration. Short-term did not result or mTORC2 pathways. Microarray analysis revealed persistent effect short-term inhibition gene expression genetic signature reminiscent normal liver. We conclude stages carcinogenesis may due represent an effective chemopreventive strategy this form cancer.

参考文章(51)
A. Medline, D. Solt, E. Farber, B. Laishes, R. Cameron, K. Ogawa, Newer insights into the pathogenesis of liver cancer. American Journal of Pathology. ,vol. 89, pp. 477- 482 ,(1977)
Tiangang Li, Udayan Apte, Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer. Advances in pharmacology (San Diego). ,vol. 74, pp. 263- 302 ,(2015) , 10.1016/BS.APHA.2015.04.003
Ning Zhang, Eagle S. H. Chu, Jingwan Zhang, Xiaoxing Li, Qiaoyi Liang, Jie Chen, Minhu Chen, Narci Teoh, Geoffrey Farrell, Joseph J.Y. Sung, Jun Yu, Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway Oncotarget. ,vol. 5, pp. 8330- 8340 ,(2014) , 10.18632/ONCOTARGET.2212
R. A. Faris, H. A. Dunsford, D. C. Hixson, B. A. Monfils, Antigenic relationship between oval cells and a subpopulation of hepatic foci, nodules, and carcinomas induced by the "resistant hepatocyte" model system. Cancer Research. ,vol. 51, pp. 1308- 1317 ,(1991)
J. D. Storey, R. Tibshirani, Statistical significance for genomewide studies Proceedings of the National Academy of Sciences of the United States of America. ,vol. 100, pp. 9440- 9445 ,(2003) , 10.1073/PNAS.1530509100
Michael Reich, Ted Liefeld, Joshua Gould, Jim Lerner, Pablo Tamayo, Jill P Mesirov, GenePattern 2.0. Nature Genetics. ,vol. 38, pp. 500- 501 ,(2006) , 10.1038/NG0506-500
Dudley W. Lamming, Gokhan Demirkan, Joan M. Boylan, Maria M. Mihaylova, Tao Peng, Jonathan Ferreira, Nicola Neretti, Arthur Salomon, David M. Sabatini, Philip A. Gruppuso, Hepatic signaling by the mechanistic target of rapamycin complex 2 (mTORC2) The FASEB Journal. ,vol. 28, pp. 300- 315 ,(2014) , 10.1096/FJ.13-237743
Dos D Sarbassov, Siraj M Ali, Shomit Sengupta, Joon-Ho Sheen, Peggy P Hsu, Alex F Bagley, Andrew L Markhard, David M Sabatini, None, Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Molecular Cell. ,vol. 22, pp. 159- 168 ,(2006) , 10.1016/J.MOLCEL.2006.03.029
Mamatha Bhat, Nahum Sonenberg, Gregory J. Gores, The mTOR pathway in hepatic malignancies. Hepatology. ,vol. 58, pp. 810- 818 ,(2013) , 10.1002/HEP.26323